Vanguard Russell 1000 Growth ETF Analysis: The Vanguard Russell 1000 Growth ETF (VONG) has an implied analyst target price of $138.70 per unit, indicating a potential upside of 10.53% from its current trading price of $125.49.
Notable Holdings with Upside Potential: Key underlying holdings of VONG, such as AAON, Alnylam Pharmaceuticals, and H & R Block, show significant upside potential based on analyst target prices, with expected increases of 12.25%, 11.38%, and 11.27% respectively.
Analyst Target Price Justification: The article raises questions about whether analysts' target prices are justified or overly optimistic, suggesting that high targets could lead to future downgrades if they do not align with recent developments.
Investor Research Recommendation: Investors are encouraged to conduct further research to assess the validity of analyst targets and their alignment with current company and industry trends.
Wall Street analysts forecast ALNY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ALNY is 500.28 USD with a low forecast of 351.00 USD and a high forecast of 570.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
20 Analyst Rating
Wall Street analysts forecast ALNY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ALNY is 500.28 USD with a low forecast of 351.00 USD and a high forecast of 570.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
16 Buy
4 Hold
0 Sell
Strong Buy
Current: 365.460
Low
351.00
Averages
500.28
High
570.00
Current: 365.460
Low
351.00
Averages
500.28
High
570.00
RBC Capital
Outperform
maintain
$500 -> $465
2026-01-20
New
Reason
RBC Capital
Price Target
$500 -> $465
AI Analysis
2026-01-20
New
maintain
Outperform
Reason
RBC Capital lowered the firm's price target on Alnylam to $465 from $500 but keeps an Outperform rating on the shares after meeting with its management team following its FY26 net product revenue outlook. On Amvuttra, the company clarified that the soft November was driven by a few one-offs and highlighted a "very impressive December", the analyst tells investors in a research note. On 2026, Alnylam announced a splashy guide, primarily driven by TTR - transthyretin amyloidosis, the firm added.
Wells Fargo
Equal Weight
downgrade
$479 -> $376
2026-01-20
New
Reason
Wells Fargo
Price Target
$479 -> $376
2026-01-20
New
downgrade
Equal Weight
Reason
Wells Fargo lowered the firm's price target on Alnylam to $376 from $479 and keeps an Equal Weight rating on the shares. The firm raised FY26 Amvuttra estimates by 6% but its R&D expenses move up to about 30% of revenues between 2026-2030, compressing operating margins to management's 30% guide vs. Street's 40%-50%.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for ALNY
Unlock Now
Truist
Buy
downgrade
$535 -> $530
2026-01-08
Reason
Truist
Price Target
$535 -> $530
2026-01-08
downgrade
Buy
Reason
Truist lowered the firm's price target on Alnylam to $530 from $535 and keeps a Buy rating on the shares. The firm updated its model, but tells investors in a research note that the fundamental views remain intact from 2025.
Oppenheimer
Oppenheimer
Outperform
initiated
$500
2026-01-07
Reason
Oppenheimer
Oppenheimer
Price Target
$500
2026-01-07
initiated
Outperform
Reason
Oppenheimer assumed coverage of Alnylam with an Outperform rating and $500 price target. The firm says Amvuttra's uptake in ATTR-CM has been impressive, delivering about $300M sales in its second full quarter post-launch. Despite Amvuttra's strong growth, Alnylam has been under pressure, mainly due to market concerns around potential deceleration of Amvuttra growth and elevating payer pushback. Although Oppenheimer anticipates Q4 2025 seasonality to impact Amvuttra sales, the firm thinks Amvuttra will continue to beat growth expectations in Q4 and beyond and anticipates upcoming sales/guidance announcements to drive 10%-20% upside in Alnylam.
About ALNY
Alnylam Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in discovering, developing, manufacturing and commercializing novel therapeutics based on ribonucleic acid interference (RNAi). Its marketed products include AMVUTTRA (vutrisiran) for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR) with polyneuropathy in adults; ONPATTRO (patisiran) for the treatment of the polyneuropathy of hATTR amyloidosis in adults; GIVLAARI (givosiran) for the treatment of adults with acute hepatic porphyria; OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1, and Leqvio (inclisiran), which is being developed and commercialized by its partner, Novartis AG, for the treatment of adults with hypercholesterolemia or mixed dyslipidemia. The Company’s clinical development programs include Cemdisiran, Fitusiran, Zilebesiran, Elebsiran, Mivelsiran and ALN-HTT02. It is developing Cemdisiran to treat complement-mediated diseases.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
